What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to officially announce and provide access to Edwards Lifesciences' financial results for the third quarter of 2019 through an accompanying press release (Exhibit 99.1).

Where can I find the detailed financial results for Q3 2019?

The detailed financial results are located in the press release furnished as Exhibit 99.1 to the 8-K filing. This press release contains the specific financial figures and operational commentary for the third quarter.

Does this 8-K contain any new business developments or material events?

This specific 8-K filing, as described, focuses solely on the release of quarterly financial results. It does not indicate the disclosure of any other material events or business developments beyond the financial performance update.

Is the information in Exhibit 99.1 considered 'filed' under the Securities Exchange Act of 1934?

No, the information furnished under Item 2.02 of this 8-K, including Exhibit 99.1, is explicitly stated as not being 'filed' for the purposes of the Securities Exchange Act of 1934, as amended. This means it is provided for informational purposes but does not carry the same legal implications as formally filed information.

EW 8-K: Earnings & Results

Summary

Edwards Lifesciences (EW) filed an 8-K on October 23, 2019, to report its financial results for the third quarter of 2019. The key takeaway for investors is the release of the company's performance for the period ending September 30, 2019, as detailed in the accompanying press release (Exhibit 99.1). This filing provides the official announcement of the company's operational and financial condition for the quarter, enabling investors to assess performance against expectations and historical trends. While the 8-K itself is a procedural filing, the attached press release (Exhibit 99.1) contains the substantive financial data. Investors should carefully review this press release for specific details on revenue, earnings per share (EPS), profitability, segment performance (e.g., Transcatheter Heart Valves, Critical Care), and any forward-looking guidance provided by the company. This information is crucial for understanding the company's ongoing business trajectory and its potential impact on future stock performance.

Key Highlights

1Edwards Lifesciences (EW) announced its third-quarter 2019 financial results via an 8-K filing on October 23, 2019.
2The filing incorporates by reference a press release (Exhibit 99.1) containing the detailed financial results for the quarter.
3Investors can access crucial performance metrics, including revenue and earnings, through the furnished press release.
4The report provides an update on the company's financial condition as of the end of Q3 2019.
5This filing serves as the official channel for the dissemination of quarterly financial performance information to the market.
6Shareholders and potential investors should consult Exhibit 99.1 for a comprehensive understanding of the Q3 2019 results.

Edwards Lifesciences Corp 8-K Report, Financial Results (Oct 23, 2019)

Summary

Key Highlights

Frequently Asked Questions